Combination chemotherapy for advanced adenocarcinoma of the lung

Sørensen, Jens Benn; Hansen, Heine H.

doi:10.1007/bf00257355

Cited by 13 publications

(7 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An explanation of this observation may be that most of the responses, both in this study and in others (S0rensen et al, 1988a;S0rensen & Hansen, 1988), were partial. Some caution must be exerted when intepretating these data.…”

Section: Discussionsupporting

confidence: 57%

“…The present state of chemotherapy for inoperable ACL indicates that at the most one-third of the patients included achieve a response to the regimens available today and complete responses seldom occur (S0rensen et al, 1988a;S0rensen & Hansen, 1988). Assessment of the influence of various prognostic factors for response is therefore pertinent when evaluating response data, in the stratification of patients, and when selecting the inclusion criteria.…”

Section: Discussionmentioning

confidence: 99%

“…Only 20-40% of the patients achieve an objective response with the best treatment regimens and the majority of responses observed are only partial (S0rensen et al, 1988a;S0rensen & Hansen, 1988). A prolonged survival for patients on chemotherapy compared with untreated patients has recently been documented in a multicentre trial, showing that the administration of chemotherapy can improve, in a modest way, the overall survival of treated patients with advanced non-small cell lung cancer (P=0.02) (Rapp et al, 1988).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications

Sørensen

Badsberg²,

Hansen³

1989

Br J Cancer

View full text Add to dashboard Cite

Summary The prognostic factors for response to chemotherapy and the prognostic impact of response status on survival, relative to other prognostic variables, were evaluated among 53 responding (9 complete responses; 44 partial responses) and 165 non-responding patients with inoperable adenocarcinoma of the lung (ACL). Multiple logistic regression analysis, including 27 pretreatment variables, revealed that the only significant predictor of response was bidimensionally measurable disease parameter (P=0.02), followed by brain metastases that were negatively correlated to response, although insignificantly (P=0.10). Univariate landmark analyses among patients alive at 8, 12, 16 and 24 weeks showed a trend towards better survival for responders compared with non-responders, but did not reach a significant level at any time (P values 0.78, 0.57, 0.23 and 0.12, respectively). Death hazard ratios for responders to non-responders were 0.91, 0.89, 0.79 and 0.73. Muftivariate regression analysis among patients alive at 16 weeks demonstrated a significant impact on survival for performance status, non-radical tumour resection, liver metastases and LDH, while the impact of response status in comparison was weak and insignificant. This reflects the unsatisfactory treatment results achieved in inoperable ACL, with the majority of responses being partial, and calls for improvement of the cytostatic treatment currently available.

show abstract

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications

Sørensen

Badsberg²,

Hansen³

1989

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…It is remarkable that 'FOM' combination treatment was activi ty beyond the rates seen with MMC and especially with 5-FU and VCR, which, as single agents, have to be considered as re latively inactive [1,3,[5][6][7][8]. 'FOM' treatment seems to be a useful palliative outpatient chemotherapy for NSCLC, since toxicity was clearly inferior to that seen in cisplatin-and/or anthracycline-containing regimens [16][17][18][19][20][22][23][24], Subjective to xicides such as alopecia, nausea, vomiting, stomatitis and neu rological signs were almost absent in our study. Hematologic toxicity was moderate without leukopenia-associated fever or bleeding complications.…”

Section: Discussionmentioning

confidence: 99%

“…'FOM' has the important advantage of an outpatient treatment. High remission rates of up to 64% were reported in some re cent trials, most including cisplatin, however, with short-lasting remissions, rare complete remissions and disappointing overall survival [16][17][18][19][20][21][22][23][24]. Toxicity was acceptable in one study [21], moderate in four [18-20,24| and severe in two studies [22,23], Variations in patient pretreatment characteristics rather than treatment effects might explain this, since these results could not be confirmed when the same regimens were reassessed in / some recent randomized trials by cooperative groups [12,[25][26][27][28][29][30][31][32][33][34][35][36][37], In fact, response rates for all these (up to six-drug) combination regimens did not exceed 37% [28,32,36], Toxici ty, however, was considerable with, for example, 276 severe or life-threatening episodes and 6 treatment-related deaths in 429 evaluable patients in one large study [25], Median response duration and median overall survival were short even in trials including patients with favorable prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

FOM: An Effective, Non-Cisplatin-Based Combination Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Low Toxicity

Thürlimann¹,

Osterwalder²,

Jungi³

et al. 1993

Oncol Res Treat

View full text Add to dashboard Cite

Background: In a single-center phase II setting the efficacy and toxicity of the combination of 5-fluorouracil, vincristine and mitomycin C were tested in patients with advanced non-small-cell lung cancer (NSCLC) in order to limit side effects and costs. Materials and Methods: Fifty-four patients with inoperable or metastatic NSCLC were treated with 5-fluorouracil 450 mg/m2 i.v. on days 1-3 and days 22-24, vincristine 1.2 mg/m² i.v. on day 22, and mitomycin C 12.5 mg/m² i.v. on day 1. ‘FOM’ treatment was repeated every 6 weeks.Results: Three out of 47 evaluable patients demonstrated a complete response of 10+, 15 and 21 months duration. Ten patients experienced partial responses of 3 to 14 months duration. The overall response rate in all 54 patients was 24% (95% confidence interval 13-38%). No change in tumor size was seen in 17 patients after 3-10 months duration (median 4.7 months). Fifty patients with a total of 190 cycles are evaluable for toxicity. Forty-one patients (82%) had worst toxicity grade 0 or 1 only. The regimen was very well tolerated on an outpatient basis.Conclusions: The acceptable activity of ‘FOM’ treatment combined with its very low toxicity makes this regimen attractive to be tested in a randomized trial versus current cisplatin- or anthracycline based combinations for advanced NSCLC, evaluating primarily quality of life and including a control arm with best supportive care.

show abstract

Considering smoking status, coexpression network analysis of non–small cell lung cancer at different cancer stages, exhibits important genes and pathways

Mortezaei

Tavallaei

Hosseini

2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Non–small cell lung cancer (NSCLC) is the most common subtype of lung cancer among smokers, nonsmokers, women, and young individuals. Tobacco smoking and different stages of the NSCLC have important roles in cancer evolution and require different treatments. Existence of poorly effective therapeutic options for the NSCLC brings special attention to targeted therapies by considering genetic alterations. In this study, we used RNA‐Seq data to compare expression levels of RefSeq genes and to find some genes with similar expression levels. We utilized the “Weighted Gene Co‐expression Network Analysis” method for three different datasets to create coexpressed genetic modules having relations with the smoking status and different stages of the NSCLC. Our results indicate seven important genetic modules having important associations with the smoking status and cancer stages. Based on investigated genetic modules and their biological explanation, we then identified 13 newly candidate genes and 7 novel transcription factors in association with the NSCLC, the smoking status, and cancer stages. We then examined those results using other datasets and explained our results biologically to illustrate some important genes in relation with the smoking status and metastatic stage of the NSCLC that can bring some crucial information about cancer evolution. Our genetic findings also can be used as some therapeutic targets for different clinical conditions of the NSCLC.

show abstract

Combination chemotherapy for advanced adenocarcinoma of the lung

Cited by 13 publications

References 65 publications

Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications

Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications

FOM: An Effective, Non-Cisplatin-Based Combination Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Low Toxicity

Considering smoking status, coexpression network analysis of non–small cell lung cancer at different cancer stages, exhibits important genes and pathways

Contact Info

Product

Resources

About